Clinical trials generate promising results for improving kidney health (opens in a new tab)

medicalxpress.com · 2026-10-22

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail

The story

Clinical trials generate promising results for improving kidney health

medicalxpress.com · 2026-10-22

The story’s checkable claims.

Read the original story

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Reading mode

Scan verdicts. Open evidence only when needed.

Claim 1 of 4Not checkedThe results of numerous high-impact Phase III clinical trials that could affect kidney-related medical care were presented in person at American Society of Nephrology Kidney Week 2026.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 4Not checkedIn the interim analysis of the Phase III ORIGIN 3 trial, atacicept achieved a statistically significant reduction in urinary protein-to-creatinine ratio at week 36, and later analysis through two years showed additional benefits, including stabilization of eGFR and a marked reduction in the risk of kidney disease progression, with safety comparable to placebo.View evidenceHide evidence

As statedweek 36; two years

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 4Not checkedIn the Phase III VISIONARY trial, sibeprenlimab reduced the risk of serious kidney function loss or kidney failure in adults with IgA nephropathy by 97% compared with placebo, with kidney function remaining stable over two years.View evidenceHide evidence

As stated97%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 4Not checkedIn the Phase III TELIGAN trial, investigators reported that telitacicept slows kidney function loss and substantially reduces the risk of kidney failure in high-risk IgA nephropathy, with a favorable safety profile.View evidenceHide evidence

As statedtwo-year findings

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results